Novel Crocetin Compound for Prevention and Therapy of Pancreatic Cancer
This invention is a novel anti-oncolytic therapy, in combination with gemcitabine or 5-FU, to fight pancreatic cancer with high efficacy and low toxicity.
In addition to pancreatic cancer, crocetin has demonstrated anti-oncolytic activity in breast, lung, cervical, leukemia, colorectal, liver, and skin cancers. It can be used both as an adjuvant therapeutic to conventional chemotherapeutic agents and alone as a chemopreventive agent.
Research by Dr. Dhar and his collaborators indicates that crocetin inhibits DNA synthesis and RNA polymerase II activity, that in turn, inhibits proliferation by impairing EGFR, phospho Cdc-2, Cdc25c, cyclin B1 and increases apoptosis by enhancing the ratio of Bax/Bcl-2 that ultimately inhibits tumor formation. Crocetin also inhibits oxidant injury due to lipid peroxidation and these antioxidant effects could be responsible for inhibition of tumor formation.